Physostigmine reduces the plasma cortisol response to methylphenidate in normal subjects

Area of Science:

• Neuroscience
• Endocrinology
• Psychiatry

Background:

• Depressed patients exhibit a reduced plasma cortisol response to methylphenidate.
• The underlying neurobiological mechanisms for this blunted response remain unclear.
• Investigating cholinergic and adrenergic pathways is crucial for understanding stimulant effects in depression.

Purpose of the Study:

• To investigate if physostigmine, a cholinergic agent, can replicate the blunted cortisol response to methylphenidate in healthy subjects.
• To explore the role of cholinergic versus adrenergic activity in mediating the cortisol response to stimulants.
• To examine the effects of physostigmine-methylphenidate interaction on other hormonal and cardiovascular markers.

Main Methods:

• Six healthy male subjects participated in the study.
• Subjects received physostigmine pretreatment followed by methylphenidate administration.
• Plasma cortisol levels, growth hormone, prolactin, and heart rate were monitored.

Main Results:

• Physostigmine pretreatment successfully reproduced the reduced plasma cortisol response to methylphenidate in healthy subjects.
• Physostigmine administration enhanced the growth hormone rise and prolactin decline following methylphenidate.
• The increase in heart rate induced by methylphenidate was attenuated by physostigmine.

Conclusions:

• Increased cholinergic activity, induced by physostigmine, can mimic the blunted cortisol response to methylphenidate observed in depression.
• This finding suggests that enhanced cholinergic rather than reduced adrenergic activity may underlie the blunted stimulant response in depressed patients.
• Physostigmine modulates the neuroendocrine and cardiovascular effects of methylphenidate, highlighting the interplay between cholinergic and adrenergic systems.